mProX™ Human CD276 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Immune Checkpoint Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human CD276 Stable Cell Line (S01YF-1023-PY170). Click the button above to contact us or submit your feedback about this product.
Taylor Miller (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Casey Jones (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 Knockdown or overexpression of CD276 in various cells.
CD276 overexpression in SCC1 and SCC23 cells triggered an upregulation of c-Jun and FOSL1 expression levels, whereas the knockdown of CD276 in HN6 cells led to a marked reduction in c-Jun and FOSL1 expression. In this context, Scr (scramble shRNA) represented the control group, while C1 and C2 denoted CD276 shRNA vectors 1 and 2, respectively.
Ref: Wang, Cheng, et al. "CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance." Cell stem cell 28.9 (2021): 1597-1613.
Pubmed: 33945793
DOI: 10.1016/j.stem.2021.04.011
Research Highlights
Coy, Shannon. et al. "Systematic Characterization of Antibody-Drug Conjugate Targets in Central Nervous System Tumors." Neuro-oncology, 2023.
Antibody-drug conjugates (ADCs) have the ability to enhance the specificity of cytotoxic drugs by specifically directing them to cells that express target antigens. Many ADCs have been approved by the FDA for the treatment of solid and hematologic malignancies, particularly those that express HER2, TROP2, and NECTIN4. Recently, a specific ADC (Trastuzumab-Deruxtecan) that targets HER2 has been shown to improve survival and decrease growth of brain metastases in patients with treatment-resistant metastatic breast cancer, even in cases where HER2 expression is low. This suggests that low levels of ADC target expression may still be sufficient for successful treatment. However, the expression of ADC targets in central nervous system (CNS) tumors is not well understood and requires further investigation.
Coy, Shannon. et al. "Systematic Characterization of Antibody-Drug Conjugate Targets in Central Nervous System Tumors." Neuro-oncology, 2023.
Pubmed:
37870091
DOI:
10.1093/neuonc/noad205
Pio Fabrizio, Federico. et al. "B7-H3/CD276 and small-cell lung cancer: What's new?" Translational oncology, 2023.
Immunotherapy has significantly impacted the treatment of various cancers, including small-cell lung cancer (SCLC). Several practice-changing trials have led to the addition of anti-PD-L1 agents, such as atezolizumab and durvalumab, to the standard platinum/etoposide regimen for first-line therapy of extensive-stage SCLC. However, the majority of patients ultimately develop resistance to these agents, creating a need for alternative immunotherapy targets. B7-H3, a member of the B7 family overexpressed in tumor tissues, has shown promising potential as a target for cancer immunotherapy. Several methods, including immunohistochemistry and flow cytometry, have been used to assess B7-H3 expression levels in lung cancer patients. Currently, there are no clinically available therapeutics targeting B7-H3, but promising preliminary clinical results have been reported for antibody-drug conjugates DS7300a and HS-20093 in pretreated SCLC patients. This review will provide an overview of B7-H3 and its inhibitors, as well as their clinical development for the management of SCLC.
Pio Fabrizio, Federico. et al. "B7-H3/CD276 and small-cell lung cancer: What's new?" Translational oncology, 2023.
Pubmed:
37865049
DOI:
10.1016/j.tranon.2023.101801
